Relationship Between C Peptide and Chronic Complications in Type-2 Diabetes Mellitus

Overview

Journal J Natl Med Assoc

Publisher Elsevier

Specialty General Medicine

Date 2005 Sep 22

PMID 16173326

Citations 22

Authors

Ramazan Sari

Mustafa Kemal Balci

Affiliations

Soon will be listed here.

Abstract

Objective: The relationship between C peptide and micro- and macrovascular complications is poorly known in type-2 diabetes mellitus. The aim of the study was to evaluatethe relationship between serum C-peptide level and chronic complications in patients with type-2 diabetes mellitus.

Patients And Methods: Three-hundred-eighteen patients (138 male, 180 female) with type-2 diabetes mellitus were included in the study. Microvascular (nephropathy, retinopathy and neuropathy) and macrovascular complications (coronary artery disease and peripheral vascular disease) were determined in all patients. In addition, presence of hypertension and smoking habit was recorded. Fasting serum glucose, lipid levels, HbA1c and C-peptide levels were measured in all patients.

Results: There were 90 (28.3%) patients with sensorial neuropathy, 48 (15.1%) with autonomic neuropathy, 72 (22.7%) with nephropathy, 84 (26.4%) with retinopathy, 135 (42.5%) with hypertension, 270 (84.9%) with dyslipidemia, 33 (10.4%) with coronary artery disease and 18 (5.7%) with peripheral vascular disease. Serum C-peptide level was higher in patients with dyslipidemia (p = 0.045), hypertension (p = 0.001), coronary artery disease (p = 0.001), peripheral vascular disease (p = 0.001) and autonomic neuropathy (p = 0.001). Serum C-peptide level was not significantly different in patients with and without sensorial neuropathy, nephropathy and retinopathy. Serum C-peptide level was significantly associated with the presence of coronary artery disease (p = 0.001), peripheral vascular disease (p = 0.001) and autonomic neuropathy (p = 0.001). There was no relationship between C peptide and sensorial neuropathy, nephropathy and retinopathy.

Conclusion: Our findings indicate a relationship between C peptide and macrovascular but not microvascular compli cations in patients with type-2 diabetes mellitus.

Citing Articles

Role of Systemic Factors in Improving the Prognosis of Diabetic Retinal Disease and Predicting Response to Diabetic Retinopathy Treatment.

Mellor J, Jeyam A, Beulens J, Bhandari S, Broadhead G, Chew E Ophthalmol Sci. 2024; 4(4):100494.

PMID: 38694495 PMC: 11061755. DOI: 10.1016/j.xops.2024.100494.

Risk Factors for Subclinical Diabetic Peripheral Neuropathy in Type 2 Diabetes Mellitus.

Gao L, Qin J, Chen Y, Jiang W, Zhu D, Zhou X Diabetes Metab Syndr Obes. 2024; 17:417-426.

PMID: 38288341 PMC: 10823870. DOI: 10.2147/DMSO.S433024.

The Correlation Between C-Peptide and Severity of Peripheral Atherosclerosis in Type 2 Diabetes Mellitus.

Wahab M, Alhabibi A, Sakr A, Zakaria M, Saleh O, Ahmad I Diabetes Metab Syndr Obes. 2023; 16:2617-2625.

PMID: 37663202 PMC: 10474844. DOI: 10.2147/DMSO.S426956.

High levels of serum C-peptide are associated with a decreased risk for incident renal progression in patients with type 2 diabetes: a retrospective cohort study.

Yang Q, Liu Y, Peng J, Pan J, Chen L, Cui J BMJ Open Diabetes Res Care. 2023; 11(2).

PMID: 36958752 PMC: 10040069. DOI: 10.1136/bmjdrc-2022-003201.

The average 30-minute post-prandial C-peptide predicted diabetic retinopathy progress: a retro-prospective study.

Pan T, Gao J, Cai X, Zhang H, Lu J, Lei T BMC Endocr Disord. 2023; 23(1):63.

PMID: 36922809 PMC: 10018901. DOI: 10.1186/s12902-023-01300-x.

References

Bain S, Chowdhury T . Genetics of diabetic nephropathy and microalbuminuria. J R Soc Med. 2000; 93(2):62-6. PMC: 1288066. DOI: 10.1177/014107680009300204. View

Samnegard B, Jacobson S, Jaremko G, Johansson B, Ekberg K, Isaksson B . C-peptide prevents glomerular hypertrophy and mesangial matrix expansion in diabetic rats. Nephrol Dial Transplant. 2005; 20(3):532-8. DOI: 10.1093/ndt/gfh683. View

Smith R, Pyke D, Watkins P, Binder C, Faber O . C-peptide response to glucagon in diabetics with and without complications. N Z Med J. 1979; 89(634):304-6. View

Knowler W, BENNETT P, BALLINTINE E . Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians. N Engl J Med. 1980; 302(12):645-50. DOI: 10.1056/NEJM198003203021201. View

King G, Buzney S, Kahn C, Hetu N, BUCHWALD S, Macdonald S . Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels. J Clin Invest. 1983; 71(4):974-9. PMC: 436955. DOI: 10.1172/jci110852. View

Mogensen C . Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984; 310(6):356-60. DOI: 10.1056/NEJM198402093100605. View

Mosier M . Circulating C-peptide and diabetic retinopathy. Diabetes Res. 1984; 1(3):151-4. View

Ewing D, Martyn C, Young R, CLARKE B . The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985; 8(5):491-8. DOI: 10.2337/diacare.8.5.491. View

Standl E, Janka H . High serum insulin concentrations in relation to other cardiovascular risk factors in macrovascular disease of type 2 diabetes. Horm Metab Res Suppl. 1985; 15:46-51. View

10.

Feldt-Rasmussen B, Mathiesen E, Hegedus L, Deckert T . Kidney function during 12 months of strict metabolic control in insulin-dependent diabetic patients with incipient nephropathy. N Engl J Med. 1986; 314(11):665-70. DOI: 10.1056/NEJM198603133141101. View

11.

Hwang D, Barseghian G, Hill L . Control of non-insulin dependent diabetes is not correlated with endogenous insulin secretion. Diabete Metab. 1986; 12(6):325-8. View

12.

Madsbad S, Lauritzen E, Faber O, Binder C . The effect of residual beta-cell function on the development of diabetic retinopathy. Diabet Med. 1986; 3(1):42-5. DOI: 10.1111/j.1464-5491.1986.tb00704.x. View

13.

Sjoberg S, Gunnarsson R, Gjotterberg M, Lefvert A, Persson A, Ostman J . Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1987; 30(4):208-13. DOI: 10.1007/BF00270417. View

14.

Snehalatha C, Mohan R, Mohan V, Ramachandran A, Viswanathan M . Pancreatic B-cell function in relation to diabetic retinopathy in Asian Indian NIDDM patients. Acta Diabetol Lat. 1988; 25(2):95-100. DOI: 10.1007/BF02581372. View

15.

Suzuki K, Watanabe K, Motegi T, KAJINUMA H . High prevalence of proliferative retinopathy in diabetic patients with low pancreatic B-cell capacity. Diabetes Res Clin Pract. 1989; 6(1):45-52. DOI: 10.1016/0168-8227(89)90056-9. View

16.

Lee T, Saltsman K, Ohashi H, King G . Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci U S A. 1989; 86(13):5141-5. PMC: 297573. DOI: 10.1073/pnas.86.13.5141. View

17.

Niskanen L, Uusitupa M, Sarlund H, Siitonen O, Pyorala K . Five-year follow-up study on plasma insulin levels in newly diagnosed NIDDM patients and nondiabetic subjects. Diabetes Care. 1990; 13(1):41-8. DOI: 10.2337/diacare.13.1.41. View

18.

Maser R, Steenkiste A, Dorman J, Nielsen V, Bass E, Manjoo Q . Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989; 38(11):1456-61. DOI: 10.2337/diab.38.11.1456. View

19.

Brichard S, van den Abbeele E, Ketelslegers J, Lambert A . Home blood glucose monitoring, glycosylated hemoglobin and fructosamine: their relationships in diabetic patients with and without residual C-peptide secretion. Diabete Metab. 1989; 15(6):388-93. View

20.

Winocour P, Jeacock J, Kalsi P, Gordon C, Anderson D . The relevance of persistent C-peptide secretion in type 1 (insulin-dependent) diabetes mellitus to glycaemic control and diabetic complications. Diabetes Res Clin Pract. 1990; 9(1):23-35. DOI: 10.1016/0168-8227(90)90005-e. View